Merck KGaA refiles oral Multiple Sclerosis drug Cladribine
Merck KGaA refiles oral Multiple Sclerosis drug Cladribine
German pharmaceutical and chemicals company Merck KGaA said Tuesday it resubmitted its application for U.S. regulatory approval of oral multiple sclerosis treatment cladribine--seven months after the Food and Drug Administration rejected its initial submission.
The FDA last November refused to file Merck's application for approval and the German group's management has since been working with the U.S. drug regulator to address the issues that led to the refusal. A Merck spokeswoman Tuesday declined to say what additional information it provided to the FDA as part of the resubmission. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1603 Views
-
Last post by frodo
-
- 1 Replies
- 1842 Views
-
Last post by frodo
-
- 0 Replies
- 1655 Views
-
Last post by frodo
-
- 0 Replies
- 1795 Views
-
Last post by frodo
-
- 0 Replies
- 1883 Views
-
Last post by NHE
-
- 0 Replies
- 1279 Views
-
Last post by frodo
-
- 0 Replies
- 3638 Views
-
Last post by frodo
-
- 0 Replies
- 2238 Views
-
Last post by frodo
-
- 0 Replies
- 1451 Views
-
Last post by frodo